Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domvanalimab and Zimberelimab in Advanced Hepatobiliary Cancers
NCT05724563Phase 2Active, not recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Jun 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of domvanalimab and zimberelimab in hepatobiliary cancer (HBC), hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), sponsored by UT Southwestern Medical Center. Primary endpoint: Objective Response Rate at 24 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
domvanalimabzimberelimab
03
Conditions
hepatobiliary cancer (HBC)hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05724563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724563.